Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGARD-VAP: Short vs Long Antibiotic Duration for VAP
NCT03382548Phase 3Completed
- Sponsor
- University of Oxford
- Start
- Feb 2018
- Primary completion
- Jan 2023
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial in ventilator-associated pneumonia (VAP) (2 arms), sponsored by University of Oxford. Primary endpoint: Composite of Mortality and VAP Recurrence at 60 days. Started Feb 2018; status: completed.
02
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03382548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03382548.